Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026

Phase 3positivedenecimigPositive

AI Analysis

Summary

Novo Nordisk presented positive interim data from the FRONTIER4 Phase 3 extension study of investigational denecimig (Mim8) for hemophilia A, demonstrating long-term safety and efficacy across multiple dosing schedules at ISTH 2026.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Interim FRONTIER4 extension study data demonstrated positive long-term safety and efficacy results across once-weekly, once-every-two-weeks, and once-monthly dosing regimens in hemophilia A participants of all ages and disease severities

Importance:7/10

Sentiment:

0.75

hemophilia Agene therapysubcutaneousISTH 2026phase 3 extension

Related Companies

$NVO

Read the original article

Published by PR Newswire Pharma on July 11, 2026 12:05 PM

Read Original